In a blow to the pharmaceutical industry, a federal court judge allowed a new Maryland law to go into effect on Sunday that permits state officials to punish generic drug makers for price gouging.

The Association for Accessible Medicines, a trade group, had argued the law — which was enacted last May and is the first of its kind in the U.S. — was unconstitutional, unnecessarily vague, and might prompt some companies to halt the sale of their medicines in the state. But U.S. District Court Judge Marvin Garbis was not persuaded.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy